Asset Details
Do you wish to reserve the book?
Interleukin-19 Abrogates Experimental Autoimmune Encephalomyelitis by Attenuating Antigen-Presenting Cell Activation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Interleukin-19 Abrogates Experimental Autoimmune Encephalomyelitis by Attenuating Antigen-Presenting Cell Activation
Do you wish to request the book?
Interleukin-19 Abrogates Experimental Autoimmune Encephalomyelitis by Attenuating Antigen-Presenting Cell Activation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Interleukin-19 Abrogates Experimental Autoimmune Encephalomyelitis by Attenuating Antigen-Presenting Cell Activation
2021
Overview
Interleukin-19 (IL-19) acts as a negative-feedback regulator to limit proinflammatory response of macrophages and microglia in autocrine/paracrine manners in various inflammatory diseases. Multiple sclerosis (MS) is a major neuroinflammatory disease in the central nervous system (CNS), but it remains uncertain how IL-19 contributes to MS pathogenesis. Here, we demonstrate that IL-19 deficiency aggravates experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, by promoting IL-17-producing helper T cell (Th17 cell) infiltration into the CNS. In addition, IL-19-deficient splenic macrophages expressed elevated levels of major histocompatibility complex (MHC) class II, co-stimulatory molecules, and Th17 cell differentiation-associated cytokines such as IL-1β, IL-6, IL-23, TGF-β1, and TNF-α. These observations indicated that IL-19 plays a critical role in suppression of MS pathogenesis by inhibiting macrophage antigen presentation, Th17 cell expansion, and subsequent inflammatory responses. Furthermore, treatment with IL-19 significantly abrogated EAE. Our data suggest that IL-19 could provide significant therapeutic benefits in patients with MS.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Animals
/ Antigen-Presenting Cells - immunology
/ Antigen-Presenting Cells - metabolism
/ Antigens
/ Ataxia
/ Disease
/ Disease Susceptibility - immunology
/ Encephalomyelitis, Autoimmune, Experimental - etiology
/ Encephalomyelitis, Autoimmune, Experimental - metabolism
/ Encephalomyelitis, Autoimmune, Experimental - pathology
/ Experimental allergic encephalomyelitis
/ experimental autoimmune encephalomyelitis
/ Histocompatibility Antigens Class II - genetics
/ Histocompatibility Antigens Class II - immunology
/ Major histocompatibility complex
/ Mice
/ Myelin-Oligodendrocyte Glycoprotein - adverse effects
/ Myelin-Oligodendrocyte Glycoprotein - immunology
/ Software
/ Spleen
/ T-Lymphocyte Subsets - immunology
/ T-Lymphocyte Subsets - metabolism
/ Toxins
